A peptide-guided prodrug incorporating a tumor-specific peptide, doxorubicin, and a pH-sensitive hydrazone bridge was developed for targeted ablation of cancer cells with minimal side cytotoxicity.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: